Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

sition-related items (93,081) 93,081 (5) - Operating income 390,024 129,766 519,790 Interest (income) expense, net 37,718 (14,719) (6) 22,999 Other (income) expense, net (3,329) 3,560 (7) 231 Gain on extinguishment of debt (4,025) 4,025 (8) - Income before income taxes 359,660 136,900 496,560 Income taxes 93,324 68,948 (9) 162,272 Net income $266,336 $67,952 $334,288 Diluted earnings per share $2.27 $2.84 Diluted weighted average shares 117,515 117,515 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations: (1) To exclude amortization of commercial intangible assets related to marketed products of $62,931 and the impact of an Indevus inventory step-up recorded as part of acquisition accounting of $11,268. (2) To exclude certain separation payments. (3) To exclude upfront and milestone payments to partners. (4) To exclude the impairment of AVEED and PRO2000 for $65,000 and $4,000, respectively. (5) To exclude Indevus transaction and separation costs of $35,009 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of ($128,090). (6) To exclude additional interest expense as a result of adopting ASC 470-20 of $15,781 and to exclude the amortization of the premium on debt acquire
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , ARDEE, Ireland, Nov. 19 Warner ... of its previously announced secondary offering of 20,000,000 of its ... per share. The selling shareholders include funds affiliated with ... by CCMP Capital) and Thomas H. Lee Partners, L.P., certain ...
... , , LYON, France, Nov. 19 ... dangerous and illegal medicines, Operation Pangea II, involving 24 ... Organization,s International Medical Products Anti-Counterfeiting Taskforce (IMPACT) to highlight ... long global initiative resulted in a series of arrests ...
Cached Medicine Technology:Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... today called for mass screening to identify people prone to ... stroke prevention policy. // ,On the eve of ... myths about strokes -- widely and wrongly believed to be ... ,"Unlike heart attacks, people know very little about strokes. It ...
... health care services provided to children with special health ... to be below their required need. //In addition, the ... their mental health care needs met. These are the ... by Harvard School of Public Health (HSPH) researchers, published ...
... were been faced by the doctors – a report from ... the BMA in Northern Ireland, say a similar case of ... A postal questionnaire addressed to all BMA workers in the ... ,More than half doctors participated in the survey revealed their ...
... Papilloma virus is a major cause of uterine cancer. According ... 70 % of Brazil’s uterine cancer cases//. Hence the Brazilian ... HPV. After the positive test results then the government plans ... are planning to conduct a campaign to vaccinate Brazilian women ...
... being organized to increase awareness of the effects of alcohol ... of drinking// are being highlighted as part of drug action ... alcohol spectrum disorders that cause physical and mental disabilities in ... the incidence of fetal alcohol spectrum disorders in Kimberley is ...
... Health had reported on Thursday that a second Dutch person ... disease, last year a woman died from the disease. ... not however disclose any further details about the patient to ... that eating contaminated meat products would have on all probabilities ...
Cached Medicine News:Health News:Health Care For Children With Special Needs Compromised 2Health News:Drug Action Week to Highlight Effects of Alcohol 2
The Natural Selection family of specialty allografts are spinal allograft devices to eliminate the need for painful autograft harvesting....
... are unique corticocancellous allografts comprised of ... unique Dovetail geometry permitting a precise ... Allografts are processed from donor vertebral ... Specially designed instruments facilitate the insertion ...
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
... Titanium Microdiscectomy System offers strength and ... The boss anteater titanium microdiscectomy system ... discs provides for less invasive procedures ... is designed to provide low profile, ...
Medicine Products: